Core Viewpoint - The company TianKang (301263.SZ) has received a drug registration certificate from the National Medical Products Administration for its compound formulation of Finasteride and Tadalafil capsules, marking a significant milestone as the first company in China to obtain this certification for this specific drug combination [1]. Group 1: Product Details - The Finasteride and Tadalafil capsules are designed to treat symptoms of benign prostatic hyperplasia (BPH), utilizing the synergistic effects of both components [1]. - Finasteride, a 5α-reductase inhibitor, helps reduce prostate volume and alleviate urinary difficulties, while Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, directly addresses lower urinary tract symptoms associated with BPH [1]. - Tadalafil also has the added benefit of improving erectile function, potentially counteracting erectile dysfunction side effects that may arise from Finasteride treatment [1]. Group 2: Market Position - As of now, no other companies in China have received a drug registration certificate for Finasteride and Tadalafil capsules, positioning the company as a pioneer in this market segment [1].
泰恩康(301263.SZ)：子公司收到非那雄胺他达拉非胶囊药品注册证书